enGene (NASDAQ:ENGN – Get Free Report) is one of 439 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare enGene to related companies based on the strength of its analyst recommendations, risk, earnings, valuation, profitability, institutional ownership and dividends.
Dividends
enGene pays an annual dividend of $1.58 per share and has a dividend yield of 24.0%. enGene pays out -97.0% of its earnings in the form of a dividend. As a group, “Biotechnology” companies pay a dividend yield of 3.1% and pay out 3,700.3% of their earnings in the form of a dividend. enGene is clearly a better dividend stock than its rivals, given its higher yield and lower payout ratio.
Volatility & Risk
enGene has a beta of -0.63, indicating that its stock price is 163% less volatile than the S&P 500. Comparatively, enGene’s rivals have a beta of 1.20, indicating that their average stock price is 20% more volatile than the S&P 500.
Institutional & Insider Ownership
Earnings & Valuation
This table compares enGene and its rivals top-line revenue, earnings per share and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
enGene | N/A | $104.74 million | -4.05 |
enGene Competitors | $156.02 million | -$17.57 million | 55.21 |
enGene’s rivals have higher revenue, but lower earnings than enGene. enGene is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Analyst Ratings
This is a breakdown of current ratings and price targets for enGene and its rivals, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
enGene | 0 | 0 | 6 | 0 | 3.00 |
enGene Competitors | 730 | 2347 | 5545 | 66 | 2.57 |
enGene presently has a consensus price target of $34.40, suggesting a potential upside of 421.21%. As a group, “Biotechnology” companies have a potential upside of 15.73%. Given enGene’s stronger consensus rating and higher possible upside, equities research analysts plainly believe enGene is more favorable than its rivals.
Profitability
This table compares enGene and its rivals’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
enGene | N/A | -63.25% | -5.65% |
enGene Competitors | -11,896.65% | -127.11% | -24.51% |
Summary
enGene beats its rivals on 10 of the 15 factors compared.
About enGene
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.